New cholesterol guidelines: Has godot finally arrived?

Annals of Internal Medicine

Volumn 160, Issue 5, 2014, Pages 354-355

  Downs, John ^a   Good, Chester ^b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONSENSUS; GENERAL PRACTITIONER; MEDICAL SOCIETY; NOTE; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84895830381     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/m13-2850     Document Type: Article

References (9)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421. [PMID: 12485966]
2. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. [Epub ahead of print] [PMID: 24239923]
3. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health [Letter]. Circ Cardiovasc Qual Outcomes. 2012;5:2-5. [PMID: 22253366]
4. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Pr; 2011.
5. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74. [PMID: 20228404]
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. [PMID: 12114036]
7. Kolata G. Risk calculator for cholesterol appears flawed. New York Times. 17 November 2013. Accessed at www.nytimes.com/2013/11/18/health/risk-calculator -for-cholesterol-appears-flawed.html?-r-0 on 9 January 2014.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. [PMID: 9613910]
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. [PMID: 16214597]